317 related articles for article (PubMed ID: 11725169)
21. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
Brooks DP; Ruffolo RR
J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
[TBL] [Abstract][Full Text] [Related]
22. Elevation of sympathetic activity by eprosartan in young male subjects.
Heusser K; Vitkovsky J; Raasch W; Schmieder RE; Schobel HP
Am J Hypertens; 2003 Aug; 16(8):658-64. PubMed ID: 12878372
[TBL] [Abstract][Full Text] [Related]
23. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.
Müller P; Cohen T; de Gasparo M; Sioufi A; Racine-Poon A; Howald H
Eur J Clin Pharmacol; 1994; 47(3):231-45. PubMed ID: 7867676
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
26. Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation.
Raasch W; Dominiak P; Ziegler A; Dendorfer A
Hypertension; 2004 Sep; 44(3):346-51. PubMed ID: 15262904
[TBL] [Abstract][Full Text] [Related]
27. No involvement of the AT2-receptor in angiotensin II-enhanced sympathetic transmission in vitro.
Nap A; Balt JC; Pfaffendorf M; Zwieten PA
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):100-5. PubMed ID: 12806592
[TBL] [Abstract][Full Text] [Related]
28. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
[TBL] [Abstract][Full Text] [Related]
29. Interactions between the renin-angiotensin system (RAS) and the sympathetic system.
Dendorfer A; Raasch W; Tempel K; Dominiak P
Basic Res Cardiol; 1998; 93 Suppl 2():24-9. PubMed ID: 9833158
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II.
Chen K; Mehta JL; Li D; Joseph L; Joseph J
Circ Res; 2004 Dec; 95(12):1167-73. PubMed ID: 15539634
[TBL] [Abstract][Full Text] [Related]
32. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
[TBL] [Abstract][Full Text] [Related]
33. [Role of the renin-angiotensin system on the sympathetic response induced by the cold pressor test in humans].
Zavala LE; Cierco M; Gutiérrez A; Garrido MR; Israel A
Invest Clin; 2007 Jun; 48(2):155-65. PubMed ID: 17598639
[TBL] [Abstract][Full Text] [Related]
34. AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Clair MJ; Krombach RS; Hendrick JW; Houck WV; Hebbar L; Kribbs SB; Rios G; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
J Card Fail; 1998 Dec; 4(4):311-23. PubMed ID: 9924853
[TBL] [Abstract][Full Text] [Related]
35. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
Spinale FG; Mukherjee R; Iannini JP; Whitebread S; Hebbar L; Clair MJ; Melton DM; Cox MH; Thomas PB; de Gasparo M
Circulation; 1997 Oct; 96(7):2397-406. PubMed ID: 9337216
[TBL] [Abstract][Full Text] [Related]
36. Effects of angiotensin II type 1 receptor antagonist on pressor responses to pulsatile compression of the rostral ventrolateral medulla in rats.
Kido H; Sasaki S; Oguni A; Harada S; Morimoto S; Takeda K; Nakagawa M
Hypertens Res; 2004 Jun; 27(6):427-32. PubMed ID: 15253108
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries.
Pantev E; Stenman E; Wackenfors A; Edvinsson L; Malmsjö M
Eur J Heart Fail; 2002 Dec; 4(6):699-705. PubMed ID: 12453539
[TBL] [Abstract][Full Text] [Related]
38. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors.
Verheijen I; Fierens FL; Debacker JP; Vauquelin G; Vanderheyden PM
Fundam Clin Pharmacol; 2000; 14(6):577-85. PubMed ID: 11206708
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of losartan and candesartan on vasoconstrictor responses in the rat.
Nossaman BD; Baber SR; Nazim MM; Detrolio JD; Kadowitz PJ
Can J Physiol Pharmacol; 2007; 85(3-4):360-71. PubMed ID: 17612645
[TBL] [Abstract][Full Text] [Related]
40. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
Lee SH; Jung YS; Lee BH; Yun SI; Yoo SE; Shin HS
J Cardiovasc Pharmacol; 1999 Mar; 33(3):367-74. PubMed ID: 10069670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
